Shilpa Gupta, MD | Authors

Articles

Expert Insights on the Potential for Triplet Regimens in RCC

September 18, 2018

Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma.

Promising Results for Pembrolizumab With Bevacizumab in mRCC

June 03, 2018

Shilpa Gupta, MD, assistant professor of Medicine in the Hematology, Oncology, and Transplantation Division, University of Minnesota, discusses phase Ib and phase II studies of pembrolizumab (Keytruda) with bevacizumab (Avastin) for the treatment of metastatic renal cell carcinoma during the 2018 ASCO Annual Meeting.